Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …

Survivors of childhood cancer are at risk of anthracycline-induced cardiotoxicity, which might
be prevented by dexrazoxane. However, concerns exist about the safety of dexrazoxane …

Background Childhood cancer survivors (CCS) are at risk for cardiotoxicity. Objectives We
sought to assess how cardiac dysfunction measurements in CCS overlap and are …

Background Cardiotoxicity is among the most important adverse effects of childhood cancer
treatment. Anthracyclines, mitoxantrone and radiotherapy involving the heart are its main …

Objectives To assess the occurrence of cardiotoxicity in patients with tumors receiving
anthracycline‐based chemotherapy, especially for sarcomas. Methods This study …

Survival in cancer is continuously improving due to evolving oncological treatment.
Therefore, cardiovascular short-term and long-term side effects gain crucial importance for …

Background Myocardial work (MW) is a new echocardiographic tool with a high sensitivity to
detect early and subtle alterations of myocardial function. We aimed to evaluate the late …

In echocardiographic surveillance of anthracycline-treated childhood cancer survivors
(CCS), left ventricular ejection fraction (LVEF) has insufficient prognostic value for future …

Background Anthracyclines and radiotherapy involving the heart region are cardiotoxic, but
the potential cardiotoxicity of vincristine remains unknown. We assessed cardiac function in …

Abnormal left ventricular contractile reserve (LVCR) is associated with adverse cardiac
outcomes in different patient cohorts and might be useful in the detection of cardiomyopathy …